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Abstract: The “antibiotic era”, characterized by the overuse and misuse of antibiotics, over the last 
half-century has culminated in the present critical “era of resistance”. The treatment of bacterial in-
fections is challenging because of a decline in the current arsenal of useful antibiotics and the slow 
rate of new drug development. The discovery of a new gene (mcr-1) in 2015, which enables bacteria 
to be highly resistant to polymyxins (such as colistin), the last line of antibiotic defence left, heralds a 
new level of concern as this gene is susceptible to horizontal gene transfer, with alarming potential to 
be spread between different bacterial populations, suggesting that the progression from “extensive 
drug resistance” to “pan-drug resistance” may be inevitable. Clearly there is a need for the develop-
ment of novel classes of anti-bacterial agents capable of killing bacteria through mechanisms that are 
different to those of the known classes of antibiotics. 1,10-phenanthroline (phen) is a heterocyclic or-
ganic compound which exerts in vitro antimicrobial activity against a broad-spectrum of bacteria. The 
antimicrobial activity of phen can be significantly modulated by modifying its structure. The devel-
opment of metal-phen complexes offers the medicinal chemist an opportunity to expand such struc-
tural diversity by controlling the geometry and varying the oxidation states of the metal centre, with 
the inclusion of appropriate auxiliary ligands in the structure, offering the opportunity to target differ-
ent biochemical pathways in bacteria. In this review, we summarize what is currently known about 
the antibacterial capability of metal-phen complexes and their mechanisms of action. 
Keywords: 1,10-phenanthroline, metal complexes, antibacterial activity, antibiotic resistance, alternative therapeutics. 
INTRODUCTION 
Antibiotic Resistance 
The discovery of antibiotics in 1939 and 1940 was an 
important historical advance in medicine for establishing a 
pivotal role in the control of untreatable and fatal infectious 
diseases [1]. The “antibiotic era” has been marked by the 
introduction of a myriad of new antimicrobials with the al-
most immediate subsequent emergence of resistance to those 
drugs [2]. The sequence of events, characterized by the over-
use and misuse of antibiotics, over the last half-century has 
led to the present critical “era of resistance” [3]. Bacterial 
resistance to antibiotics has evolved and now impacts sig-
nificantly on public health, responsible for high rates of mor-
tality and morbidity globally [4]. Over 13 million deaths 
occur worldwide as a result of the emergence of new 
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infectious diseases and the re-emergence of diseases caused 
by multidrug resistant (MDR) strains of bacteria [3]. The 
development and spread of antimicrobial resistance is related 
to (i) a lack of public knowledge about antibiotics causing 
human overuse/misuse of antibiotics and unnatural selective 
pressure on bacteria, (ii) misuse of antibiotics in animal feed 
stocks associated with food production, (iii) natural process 
of evolution of bacterial resistance to antibiotics and (iv) a 
diminished interest in the development of antibiotics within 
the pharmaceutical industry [1, 5]. The onset of the “era of 
resistance” has seen antibacterial drugs become less effective 
or even ineffective [6]. Furthermore, therapeutic options for 
the treatment of infections have become limited, leading 
frequently to recurrent infections, treatment failure and in-
crease of morbidity and mortality, resulting in a global health 
emergency [1]. 
The big challenge for public health is the development 
and/or implementation of effective strategies to decrease the 
emergence and spread of antimicrobial resistance [1]. The 
magnitude of the problem worldwide and the impact on hu- 
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man health and on the costs for the health-care sector are 
worrying. Infection by drug-resistant bacteria requires the 
administration of high doses of antibiotics, resulting in 
higher drug toxicity, longer hospital stays and higher mortal-
ity [7]. Because of this, the annual impact of resistant infec-
tions is estimated to be US$ 21 to 34 billion in excess health 
care costs and US$ 8 million additional hospital days in the 
United States and over €1.6 to 2.5 billion additional hospital 
days in the European Union [5, 6]. Bacteria are responsible 
for approximately 90% of all hospital acquired infections, 
with immuno-compromised patients being more susceptible 
to serious infections, with higher mortality rates than people 
with healthy immune systems. The risk of fatality associated 
with infections caused by resistant bacteria as compared to 
antibiotic sensitive bacteria is much higher. Furthermore, in 
most cases of acquired infections involving resistant bacteria 
the risk of fatality is exacerbated by prolonged bacterial ex-
posure as a result of delayed or a lack of an appropriate ther-
apy, and not just because of issues associated with any in-
creased in the virulence of the organism [1]. 
The microorganisms that are mainly involved in the re-
sistance process are called the ESKAPE pathogens - Entero-
coccus faecium, Staphylococcus aureus, Klebsiella pneumo-
niae, Acinetobacter baumanii, Pseudomonas aeruginosa and 
enterobacteriaceae - emphasizing their capacity to “escape” 
from common antibacterial treatments [4]. The pathogens 
that present the greatest challenges are the multidrug resis-
tance (MDR) and extensively drug resistant (XDR) strains. 
MDR strains are defined when they are non-susceptible to 
three or more antimicrobial classes, while XDR strains are 
non-susceptible to all antimicrobials [4]. Of particular con-
cern are multi- and methicillin-resistant S. aureus (MRSA), 
vancomycin-resistant Enterococcus (VRE), P. aeruginosa, 
Escherichia coli, Mycobacterium tuberculosis and K. pneu-
moniae producing extended spectrum β-lactamases (ESBL) 
and carbapenemases [1].  
Bacteria can be intrinsically resistant to therapeutic 
agents and it happens through inherent (natural) resistant. 
Otherwise, bacteria can be multidrug resistant and it occurs 
when they are transformed through the acquisition of new 
genetic material from other resistant organisms. Normally 
this process is called horizontal gene transfer (HGT) and it 
is performed by bacterial conjugation, transduction, trans-
formation or biofilm formation to spread drug resistance 
[7]. Transposons in bacteria can facilitate the direct or indi-
rect transfer and incorporation of drug resistance genes into 
the host's genome or plasmids. HGT has recently been re-
ported as multidrug resistance in bacteria can also be 
caused by chromosomal mutations and the regulation of 
resistant genes. Mechanisms of this type can be classified 
into: (i) inactivation or modification of drugs; (ii) alteration 
of a target site of antibiotics (it is found that many bacteria 
are resistant to antibiotics through this mechanism); (iii) 
acquisition of alternative metabolic pathways to those in-
hibited by antimicrobials; (iv) decreasing drug permeability 
of drugs across the cell membrane before they can reach 
their target sites and exert their effects on bacteria; (v) en-
zymatic modification or degradation of the antimicrobial 
agents; (vi) over-expression of the drug target; and (vii) 
increasing the active efflux pumps that pump out or extrude 
antibiotics from the cell [1, 7, 8]. 
Implications of Biofilms 
It is a particular concern when bacteria become resistant 
to various antimicrobial agents simultaneously and mainly 
when they form biofilms [1]. An estimated 80% of bacterial 
infections in humans are caused by biofilms, and the Centers 
for Disease Control have declared biofilms to be the most 
pressing clinical impediment of the century [9]. Biofilm 
formation is particularly problematic with implantable de-
vices such as prosthetic hips, which often require surgical 
removal to eliminate the infection. Biofilm formation is a 
complex process involving multiple bacterial signaling sys-
tems including quorum sensing (QS), nutrient and chemical 
signal response, and extra-cellular matrix formation [9]. A 
bacterial biofilm is a cooperative community of unicellular 
organisms attached to a solid surface or encased in a hy-
drated matrix of polysaccharide, protein and nucleic acids. 
The extracellular polysaccharides (EPS) are an insoluble and 
slimy secretion that is released by bacterial cells, encapsulat-
ing adjoining cells in a well-organized and structured matrix 
capable of assisting in dissemination of nutrients that are 
necessary for cell growth, to bind external nutrient molecules 
required for cell sustenance and growth, to provide protec-
tion from external environmental stresses that includes pro-
tection from antibiotics, disinfectants and from dynamic en-
vironments [10]. 
Biofilms are usually formed through several steps (i) the 
initial step in biofilm formation is the adherence of bacteria 
to a foreign body or biomaterial; (ii) the transformation from 
reversible to irreversible attachment is a relatively rapid 
process, taking place within a few minutes or less; (iii) bac-
terial adhesion is mediated by fimbriae, pili, flagella and 
extracellular polymeric substance, which form a communica-
tion bridge between bacteria and the conditioning films; (iv) 
the aggregation and accumulation of adherent bacteria lead 
to the formation of multiple cell layers as the biofilm ma-
tures, and (v) the last step is the detachment of bacteria from 
the biofilm into a planktonic state, which allows them to 
initiate a new cycle of biofilm formation [7, 10]. Some hy-
potheses for drug resistance in biofilms have been reported 
in the literature: (i) in biofilms, the penetration of antibiotics 
is slow and incomplete resulting in an in-effective response 
to antibacterial agent which must diffuse and penetrate into 
the bacterial cells; (ii) a concentration gradient of a meta-
bolic substrate or product leads to zones of slow-growing or 
non-growing bacteria with less uptake of antimicrobial 
agents than in planktonic cells; (iii) an adaptive stress re-
sponse is expressed by some bacteria to cope with environ-
mental fluctuations, such as temperature change, oxidative 
stress or DNA damage; and (iv) a small fraction of bacteria 
differentiate into a highly protected persistent state that re-
duces the susceptibility of their biofilm to antibiotics [11, 
12]. 
The Limitations of Current Therapeutic Strategies 
The treatment of bacterial infections is becoming more 
difficult because of a decline in the current arsenal of useful 
antibiotics, the development of antibiotic resistance and the 
slow rate of new drug development [1, 13]. Recent review 
articles in Chemistry World by King are highly critical of the 
serious underinvestment globally by governments and 
1282    Current Topics in Medicinal Chemistry, 2017, Vol. 17, No. 11 Viganor et al. 
N
S
O
OH
O
N
H
O
R H
Penicillin
O
O
OCH3
CH3
O
OH
CH3
O
HO
O
N
CH3
H3C
CH3
OH
CH3
CH3
O
H3C
C2H5
HO
H3C
OH
H3C
O
CH3
Erythromycin
N
O
OH
N
HN
O
F
Ciprofloxacin
!-lactams Macrolides Fluoroquinolones
 
Fig. (1). Typical structures of theβ-lactams (penicillin), Macrolides (erythromycin) and fluoroquinolones (ciprofloxacin). 
 
pharmaceutical companies for the development of new an-
timicrobial drugs, even though predictions are that the cost 
of antimicrobial resistance (AMR) will be 300 million pre-
mature deaths and up to $100 trillion lost to the global econ-
omy by 2050 [14, 15]. The US market for antibacterials is 
dominated by six antibacterials which fall into just three 
structural classes, the β-lactams (Rocephin®, Augmentin®), 
macrolides (Zithromax®, Biaxin®), and fluoroquinolones 
(Cipro®, Levoquin®) (Fig. 1) [16]. This limited number of 
structural classes, in combination with ineffective manage-
ment of drug usage, is at the heart of the cause of the current 
“era of resistance” crisis.  
There is also a lack of diversity in the cellular target of 
the known antibiotics. Almost all clinically used antibiotics 
inhibit DNA, RNA, protein, or cell wall synthesis, and there 
are less than twenty-five molecular targets that account for 
their activity. The gravity of the crisis is appreciated as we 
witness such developments as the resistance against glyco-
peptide antibiotics, like vancomycin or teicoplanin, being 
observed with increasing frequency and resistance emerging 
within one year for the recently introduced oxazolidinones. 
The discovery of a new gene (mcr-1) in 2015, which enables 
bacteria to be highly resistant to polymyxins, such as colistin 
(Fig. 2), the last line of antibiotic defence left, heralds a new 
level of concern for the “era of resistance” as this gene is 
susceptible to horizontal gene transfer, with alarming poten-
tial to be spread between different bacterial populations. This 
discovery is very significant as it suggests that the progres-
sion from extensive drug resistance to pan-drug resistance 
may be inevitable [17]. 
The resistance problem is exacerbated by the statistic that 
bacteria in biofilm communities can be up to 1000-fold more 
resistant to eradication compared with their planktonic coun-
terparts. Indeed, very few chemical scaffolds have been iden-
tified that can inhibit or disperse bacterial biofilms. An illus-
tration of the lack of development of novel antimicrobials is 
the fact that only five new compounds have been approved 
over the last twelve years [18]. Both, persistence and spread 
of antibiotic resistance, in combination with decreased effec-
tiveness and increased toxicity of current antibiotics have 
emphasized the urgent need to search alternative sources of 
antibacterial substances [1]. 
There is clearly a requirement for the development of 
new antibacterial agents and given the mechanisms associ-
ated with resistance in bacteria, there is a need to ensure that 
new approaches to drug development involve compounds 
that can target bacterial cells in a completely different way to 
those associated with the known antibiotics. In this review, 
we explore the potential of inorganic medicinal chemistry as 
an alternative approach to developing antibacterial therapeu-
tics, with a specific focus on the mechanisms of action of 
metal complexes containing 1,10-phenanthroline ligands.  
INORGANIC MEDICINAL CHEMISTRY 
Inorganic medicinal chemistry has a relatively short his-
tory as a specific field, beginning in the 1970’s with the dis-
covery and clinical development of the successful anticancer 
drug cisplatin [19]. The design and synthesis of coordination 
complexes with novel structures and exhibiting biological 
activity, such as antimicrobial, anti-inflammatory, antioxi-
dant and anticancer, establishes this exciting field as offering 
great potential to improve the quality of life [20]. Inorganic 
medicinal chemistry offers an alternative approach to organic 
drug development through opportunities for the design of 
therapeutics with the ability to target different biochemical 
pathways [21]. The development of drugs that incorporate 
metal ions into their molecular structure offers the medicinal 
chemist an opportunity to exploit structural diversity, vary 
oxidation states of the metal and also offer the possibility of 
improving the activity of an established organic drug through 
its coordination to the metal centre [22, 23]. The antimicro-
bial capabilities of metals have been known for thousands of 
years, with historical applications in water and food preser-
vation (Cu and Ag), agriculture (Cu) and medicine (Ag, Cu, 
Hg, Te, Mg and As) [24]. The medicinal use of metals as 
antimicrobials remained prevalent until the discovery of the 
“cillin” antibiotics in the 1920’s which then saw their appli-
cations decline in popularity. Today, the burgeoning threat of 
multidrug resistant microbes to public health and the dearth 
of new clinically efficacious antibiotics have resulted in a 
renaissance in the use of antimicrobially-active metal ions 
and their complexes. Interdisciplinary research in the field of 
inorganic medicinal chemistry is advancing our knowledge 
of metal toxicity and facilitating the design of metal-
containing compounds as effective and targeted antimicrobials 
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Fig. (2). Structure of the polymyxin, colistin. 
 
offering a realistic alternative to antibiotics [25]. We do not 
associate the activity of most conventional antibiotics with 
the presence of metal ions. However, a number of antibiotics 
are known to require coordinated metal ions to function 
properly [25]. These include bleomycin (BLM), streptonigrin 
(SN), bacitracin and albomycin which depend on coordi-
nated metal ions to maintain proper structure and/or biologi-
cal function. The term ‘metalloantibiotic’ has been coined to 
describe such metal ion dependent antibiotics and they are 
known to exert their bioactivities through interactions with a 
variety of biomolecules including DNA, RNA, proteins lip-
ids and receptors. More recently, the term ‘metalloantibiotic’ 
has been applied, more generally, to metal complexes that 
exhibit antibacterial capability.  
BIOINORGANIC CHEMISTRY OF BACTERIA 
An estimated 25% of all proteins in cells require at least 
one transition metal ion to ensure function [26], and for the 
known structurally characterised enzymes, the transition 
elements (as proportions) that have been identified as cofac-
tors are, Zn (9%), Fe (8%), Mn (6%), Cu (1%), Co (1%), Ni 
(0.5%), V (<1%), Mo(<1%), W (<1%) [27]. Many metal-
loenzymes are involved in the regulation of the metabolic 
and physiological processes essential for microbial cell 
growth and homeostasis [26, 28, 29]. For example, iron is 
required for important cellular processes including DNA 
replication, central metabolism and respiration, whilst en-
zymes containing Zn(II) and Mn(II) centres are crucial for 
detoxifying reactive oxygen species (ROS) and reactive ni-
trogen species (RNS) [30]. Stringent control of the homeo-
stasis of transition metal ions is essential for all life forms. 
Limiting the availability of these metal ions to the pathogen, 
for example through the imposition of nutritional immunity 
by infected mammalian host cells, will disrupt homeostasis, 
compromise cellular vitality and ultimately kill the organism 
[31]. Furthermore, the use of selected chelators to sequester 
metal ions has been shown to inhibit the biological function 
of metal-dependent proteins in microbes interfering with 
microbial nutrition, growth and development, cellular differ-
entiation, adhesion to biotic and abiotic structures as well as 
controlling the progression of the in vivo infection [32, 33]. 
On the other hand, the ability of microbes to scavenge metals 
from vital metalloenzymes in host cells is considered an im-
portant virulence attribute [34]. Indeed, an important facet of 
infectious disease is the relentless contest between host and 
pathogen for transition metal ions. 
Whilst relatively small quantities of metal ions are re-
quired to sustain microbial growth and reproduction, expo-
sure to high concentrations can be devastating. Not surpris-
ingly, the host cell immune system attempts to exploit this 
vulnerability by overloading the bacterial cells with excess 
metals in their mission to destroy the pathogen [34]. Under 
such duress, the microbes deploy a range of resistance 
strategies, which includes restricting uptake, extra- and intra-
cellular sequestration, enzymatic detoxification and efflux, in 
their defence against metal poisoning [34, 35]. Lemire et al. 
[24] categorised the antimicrobial mechanisms of metal tox-
icity into 5 specific mechanisms fully recognising that these 
categories were not confined to specific microbial cells or 
metals. An emphasis was also made on the importance of the 
molecular interactions and functions for metal toxicity. The 
5 proposed mechanisms were a) Protein dysfunction and 
impaired enzyme activity due to oxidative protein damage or 
exchange of a structural or catalytic metal; b) Production of 
reactive oxygen species (ROS) and antioxidant depletion 
demonstrated in numerous metal toxicity studies particularly 
for iron [36] and copper [37]; c) Impaired cell membrane 
function and loss of membrane potential; d) Interference 
with nutrient uptake and assimilation which can directly af-
fect gene expression and the microbial signalling mecha-
nisms of quorum sensing and e) Genotoxicity that was dem-
onstrated by catalytic Fenton-type reactions in Fe which was 
linked to DNA damage and cell death [38]. The authors fur-
ther reported that microbiological studies on genotoxicity 
have demonstrated toxicity with Mn(II), Cr(VI), Co(II), 
Cd(II), Mo(IV), Sb(III) and As(III) but not Ni(II), Cu(II), 
Te(IV), Pb(II), Ag(I) and Al(III) [1]. This highlights the fact 
that metals have their own unique biochemical mechanisms 
of toxicity in microbial cells and they may trigger several of 
these proposed mechanisms simultaneously, but further stud-
ies on the association between each of these mechanisms and 
microbial cellular death processes as the result of metal tox-
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icity are needed at a molecular level. Moreover, further in-
vestigation into the precise role of these mechanisms in 
metal resistance and biofilm formation is important to under-
stand the potential mode of action of novel inorganic drugs.  
1,10-PHENANTHROLINE 
1,10-phenanthroline (phen) (Fig. 3) is a heterocyclic or-
ganic compound which exerts excellent in vitro antimicro-
bial activity against a broad-spectrum of bacterial and fungal 
pathogens [39-42]. The in vitro antibacterial action of phen 
has been demonstrated on a range of bacterial species [40, 
41, 43-45]. Ostensibly, the antimicrobial activity of phen can 
be significantly modulated by modifying its structure by ei-
ther extending its backbone at the -5,6- position or by the 
substitution of the aromatic protons by suitable substituents 
(Fig. 4) [44]. Phen, as a π donor, is also known to form 
‘charge-transfer’ derivatives with organic and inorganic 
groups to yield organic complexes and quaternary salts that 
also exhibit significant in-vitro antibacterial activity [29, 46, 
47].  
 
N N
2
3
4
5 6
7
8
9  
Fig. (3). Structure of 1,10-phenanthroline (phen) with numbering 
for substituents. 
 
The antimicrobial capability of phen is associated with its 
properties as a chelator and its ability to sequester metal ions 
in biological systems [32]. Chelation activity is the combina-
tion of a metal ion with a chemical compound that coordi-
nates the formation of a chelating ring, often used to remove 
heavy metals ions. For many microorganisms, phen has the 
capability of inhibiting the biological role of metal-
dependent proteins, interfering with metal acquisition, 
bioavailability and metabolism for crucial reactions, disturb-
ing the microbial cell homeostasis and culminating in the 
blockage of microbial nutrition, growth, development, cellu-
lar differentiation, adhesion to biotic and abiotic structures as 
well as playing an important role in the in vivo infection pro-
gression [48, 49]. The iron chelating proteins, transferrin and 
lactoferrin, have evolved in mammalian cells for the acquisi-
tion of iron via specific pathways. These naturally occurring 
chelators have been shown to have potential to prevent the 
growth of microbial pathogens and their proliferation in host 
cells [50, 51]. Therefore, synthetic metal chelators, such as 
phen, have received substantial attention as therapeutic 
agents because of their ability to alter the metabolism and 
homeostasis of essential metals such as iron, copper and 
zinc. Furthermore, upon sequestration of metal ions the re-
sulting metal-phen complexes are themselves capable of 
exerting a biological response in their own right [32]. Ma-
cLeod and his co-workers demonstrated the importance of 
the chelating ability of phen in 1952 when they showed that 
both its 1,7- and 4,7-phenanthroline isomers were inactive 
against lactic acid bacteria [52]. Furthermore, the interaction 
of phen with DNA appears to be dependent on the availabil-
ity of metal cations, such as Cu2+ [32]. 
In 2008, Soares et al. demonstrated that the cell surface 
and secreted molecules of group B Streptococcus (GBS) are 
often essential virulence factors involved in the adherence of 
the bacteria to host cells or that they are required to suppress 
the defense mechanism of hosts. Cleavage of the host ex-
tracellular matrix by GBS may be a relevant factor in the 
process of bacterial dissemination and/or invasion. These 
workers demonstrated that phen, acting as a metallopeptidase 
inhibitor, completely inhibited this cleavage. Notably, phen 
(0.1 mM) strongly blocked GBS growth as well as its inter-
action or invasion in human cell lineages. Herein, GBS strain 
90356 adhered to and invaded efficiently to the Human Um-
bilical Vein Endothelial Cells (HUVECs) model. But the 
adhesive property of this strain 90356 was significantly in-
hibited by ~93% and also its intracellular viability (invasion) 
in HUVECs was strongly reduced, by ~82%. The authors 
presumed that the metallopeptidases assist GBS in deriving 
essential nutrients from human proteins in maintaining GBS 
metabolic machinery and physiological processes such as 
cellular growth [53].  
In 2015, Tay et al. tested 1,10-phenanthroline-5,6-dione 
(phendione) (Fig. 4), as a potentially novel antimicrobial 
agent against Enterococcus and it effectively eradicated E. 
faecalis biofilms. It was proposed that the antimicrobial ac-
N N
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O O
N N
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Fig. (4). Examples of modified phen structures. 
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tivity of phendione appears to be related to its ability to se-
lectively disturb essential metals (Zn2+, Fe2+, Ca2+, Cu2+, 
Co2+, Mn2+ and Ni2+) required for bacterial metabolism and 
physiological processes. Therefore, chelation of these metal 
ions is responsible for the disruption of cellular vitality and 
subsequent cell death. In this study, they demonstrated the 
ability of phendione to inhibit the growth of E. faecalis in the 
presence of excess Zn2+ ions, suggesting that phendione ex-
erts its antimicrobial effects through its ability to chelate 
Zn2+[54]. 
METAL COMPLEXES OF 1,10-PHENANTHROLINE 
Historical Perspective 
Phen is an avid chelating agent which forms complexes 
with a range of metals [55]. Indeed, the biological activity of 
phen has been attributed to its ability to sequester trace met-
als and the resulting metal complexes are believed to be the 
actual active species [56]. Metal complexes containing phen 
have shown significant potential as broad-spectrum agents 
capable of eliciting cytotoxicity towards diseases and infec-
tions manifested by cancer, [42, 57] viruses, [58] bacteria 
[59] and fungi [60, 61]. Phen, its related organic compounds 
and their corresponding metal complexes are known to in-
hibit the growth of fungal pathogens by damaging their mi-
tochondrial function, uncoupling respiration, causing non-
specific DNA cleavage, disrupting cell division and inducing 
gross distortions in fungal cell morphology [61, 62]. In 1969, 
Dwyer et al. published their comprehensive, landmark trea-
tise on the in vitro and in vivo antibacterial activities of dica-
tionic Mn(II) Fe(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and 
Ru(II) chelates containing phen and substituted phen (R-
phen) ligands [43, 44]. The results demonstrated that the 
metal chelates were more active than the ‘metal-free’ phen 
ligand, against M. tuberculosis, S. aureus, S. pneumonia, C. 
Perfringens, E. coli and P. Vulgaris. With the exception of 
the anti-tubercular profiles, the antibacterial activity was 
largely independent of the type of metal present. These phen 
chelates were also shown to be useful clinically as topical 
antimicrobials but selected compounds were found to be 
ineffective against mice infected with M. tuberculosis, S. 
aureus and S. pneumonia, when administered parenterally. 
Whereas cationic metal-phen complexes can be bacte-
riostatic [43] and bactericidal [39] towards many Gram-
positive bacteria they are less effective against Gram-
negative organisms. This activity trend has been explained in 
terms of the high polar lipid content of the cell walls of 
Gram-negative bacteria and the consequent impact on the 
ability of the complexes to reach vital membrane or intracel-
lular sites [43]. In 1970, Cade et al. reported that, in-vitro, 
metal complexes of 3,5,6,8- or 3,4,7,8-tetramethyl-phen 
(metal = Ni(II), Fe(II), Co(II), Cu(II), Zn(II), Cd(II), Mn(II), 
Ru(II)), the metal-free phen hydrochlorides and their quater-
nary salts were bactericidal to veterinary samples of Erysipe-
lothrix rhusiopathiae and Fusiformis nodosus [63]. Resistant 
variants of the bacterium E. rhusiopathiae were not pro-
duced after repeated subculture in the presence of the com-
plexes, [Cu(3,4,7,8-tetramethyl-phen)2]X2 (X = benzoate or 
acetate). A similar result had been observed for Staphylococ-
cus aureus, M. tuberculosis, E. coli, C. albicans and Tricho-
phyton mentagrophytes in that they develop little resistance 
to this type of complex [40, 64]. Based on these results it 
was suggested that the complexes offered potential as thera-
peutics to treat erysipelas in pigs, and that they may also be 
beneficial in the treatment of other topical bacterial infec-
tions. Furthermore, [Cu(3,4,7,8-tetramethyl-phen)2]X2 (X = 
benzoate or acetate) was also shown to be at least as effec-
tive as solutions of formalin and dioxyethyl laural ammo-
nium chloride in addressing foot-rot in sheep. Extensive mi-
crobiological and pharmacological studies of this class of 
phen-chelate led to the clinical investigation of the highly 
stable Ni(II) and Fe(II) complexes of the 3,4,7,8-tetramethyl-
phen ligand [40, 64]. These complexes were shown to ex-
hibit a wide spectrum of antimicrobial actions and to pro-
duce negligible toxic responses in skin, subcutaneous tissues 
and mucous membranes [64]. Preliminary studies had shown 
that the complexes were effective in controlling infections 
due to clinical isolates of S. aureus. The Ni(II) complex was 
as effective as hexachlorophene, when deployed as a preop-
erative skin preparation, in reducing the incidence of postop-
erative staphylococcal wound infection. Furthermore, the 
Ni(II) complex was also as effective as hexachlorophene in 
the prophylaxis of staphylococcal infection in patients un-
dergoing elective obstetric or gynaecological surgery [65]. 
This complex also controlled secondary infection in adoles-
cents with persistent acne vulgaris.  
In 1970, Cade et al. also examined the clinical applica-
tions of Mn(II) complexes of 3,4,7,8-tetramethyl-phen as 
topical treatments for a variety of skin conditions, including 
chronic dermatological infections due to dermatophytes (e.g. 
Malassezia furfur, Trichophyton rubrum) or Candida species 
[66]. The complexes induced a significant reduction in the 
microbial infection in approximately 50% of cases, with in-
fection due to Gram-positive bacteria generally more respon-
sive to treatment than that due to Gram-negative bacteria. No 
noteworthy irritation or sensitization of the underlying der-
matosis or dermatomycosis was observed, and, furthermore, 
significant microbial resistance did not develop. 
These early results clearly demonstrated the antibacterial 
chemotherapeutic potential of metal complexes of 1,10-
phenanthroline. The research was performed at a times when 
the antibiotic era was at its height and consequently the sig-
nificance of the results was not embraced by the pharmaceu-
tical sector. More recently there has been a surge in interest 
in the antimicrobial applications of metal-based compounds, 
with metal complexes incorporating phen ligands prominent, 
and it is imperative that we strive to fully understand how 
these complexes exert their biological activity and how they 
differ from the resistance-prone antibiotics.  
BACTERIAL CELL WALL PERMEABILITY  
Like all cells bacteria have a cytoplasmic membrane, 
consisting of a phospholipid bilayer and proteins, which per-
forms all of the general functions of a cell membrane (eg. 
cytoplasm protection, permeability barrier and selective 
transport of molecules into and from the cell) but differs 
from the cell membrane in eukaryotes as it does not contain 
sterols and it comprises a wider variety of fatty acids and a 
higher content of phospholipids [67, 68]. Bacteria also differ 
from eukaryotes in that they must be able to survive in much 
harsher environments and therefore they possess a robust cell 
wall which protects their cytoplasmic membrane and pre-
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vents chemical, biological and physical damage to the organ-
ism [67]. Gram-positive cells have cell walls composed of a 
thick layer of peptidoglycan and also of two types of teichoic 
acids inlaid in their structure: wall teichoic acids, which are 
coupled to peptidoglycan, and lipoteichoic acids, which are 
anchored to the cell membrane. The peptidoglycan layer is 
made up of repeating units of the disaccharide N-acetyl glu-
cosamine-N-actyl muramic acid cross-linked by pentapeptide 
side chains that play an important role in physical strength 
and bacterial shape as well as in cell division, morphological 
differentiation and adaptive responses [68, 69]. Teichoic 
acids are long anionic polymers that bind cations playing a 
role in cation homeostasis. Additionally, networks of metal 
cations between wall teichoic acids also influence the rigid-
ity and porosity of the cell wall and profoundly affect the 
interactions of bacteria with other cells or molecules [68]. 
The cell wall in Gram-negative cells does not contain 
teichoic acid and they typically have a much thinner pepti-
doglycan layer covered by an outer membrane [70]. The 
outer membrane is a lipid bilayer, a distinguishing feature of 
Gram-negative bacteria, as Gram-positive bacteria lack this 
structure. It is composed of glycolipids - mainly lipopolysac-
charides (LPS), also known as endotoxins responsible for 
much of the toxicity of Gram-negative bacteria, and by two 
classes of proteins: lipoproteins and β-barrel transmembrane 
proteins. LPS molecules bind each other avidly, especially if 
cations like Mg++ are present to neutralize the negative 
charge of phosphate groups present on the molecule, and 
form a non-fluid continuum barrier very effective for hydro-
phobic molecules. The transmembrane proteins are β sheets 
wrapped into cylinders and some of them, such as the porins 
(OmpF and OmpC), allow the passive diffusion of small 
hydrophilic molecules (i.e. mono- and disaccharides, amino 
acids, molecules ~700 Daltons) across the outer membrane 
[68, 71, 72]. Due to the limited diameters of passive diffu-
sion channels, bulky molecules (i.e. iron–siderophores and 
complex oligosaccharides) are assumed to be taken up exclu-
sively by active transporters [72]. 
Several classes of molecules can pass across the outer 
membrane without accessing the channels of porins, these 
include hydrophobic substances such as detergents, un-
charged antibiotics, enzymes like nucleases, phosphatases, 
kinases, proteases, etc.) [73]. But, in general, porins are the 
major outer membrane proteins with important permeability 
barrier properties, which define the size exclusion limit for 
hydrophilic molecules by limiting the size and the rate of the 
passage of the molecules through these channels, restricting 
molecules of similar sizes to the diameters of the porin chan-
nels [73]. The conception of “exclusion” reflects the prob-
ability that these substances are not taken up across the outer 
membrane sufficiently to cause physiological effects on 
cells, involving semi-selective exclusion of potentially harm-
ful molecules and affording Gram-negative bacteria an ad-
vantage in surviving in lethal environments [73]. The size 
exclusion molecular properties of the pores in the outer 
membrane are typical of Gram-negative bacteria. The Gram-
positive cell wall is porous and has a high molecular exclu-
sion limit of >100000 g.mol-1. It means that peptidoglycan 
structure provides rigidity and protection to the cell, but is 
unlikely to be a contributing factor to any limiting of uptake 
of molecules [71, 74, 75]. For example, E. coli and S. typhir-
nuriurn outer membranes are permeable for hydrophilic sol-
utes up to 600 - 800 g.mol-1. However, solutes up to 3000 - 
9000 g.mol-1 can penetrate the outer membrane of P. aerugi-
nosa. And still there is some evidence that the exclusion mo-
lecular weight of certain “exotic” Gram-negative bacteria 
would be as large as 20000 g.mol-1 [75, 77]. But even the 
molecular exclusion limit of P. aeruginosa being larger than 
that of E. coli, the outer membrane permeability of P. aeru-
ginosa has been determined to be approximately 8% of that 
of E. coli [75, 78]. This is because most of the P. aeruginosa 
pores appear to be nonfunctional, restricting the rate of up-
take. And low outer membrane permeability along with ef-
fective efflux mechanisms is responsible for the high intrin-
sic antibiotic resistance of P. aeruginosa [71, 75, 78]. There-
fore, the presence of the outer membrane, as a very effective 
and selective permeability barrier, greatly decreases the per-
meability to antibacterials, and it is regarded as a key 
mechanism of drug resistance (or sensitivity) in many Gram-
negative bacteria [70, 79]. For compounds to act as antibac-
terials it is generally accepted that they must be lipophilic 
and be capable of permeating the cell wall and cytoplasmic 
membrane of bacteria [80]. Ironically, ionic silver (Ag+) is a 
well-known antimicrobial, in its own right, and its activity 
has been linked to its ability to bind to bacterial cell surfaces 
and interact with proteins involved in cell wall synthesis [81, 
82].  
CELL WALL PERMEABILITY AND ACTIVITY OF 
METAL-PHEN COMPLEXES 
Cationic metal ions do not easily cross the cell membrane 
of bacteria and in nature uptake of essential metal ions is 
achieved by transporter proteins which effectively wrap the 
cations up in a hydrophobic blanket. The same effect can be 
achieved by complexation with hydrophobic chelating 
ligands such as phen. The ability of such phen-based com-
plexes to cross the cell membrane is explained in the context 
of Overtone’s concept of cell permeability [83] and 
Tweedy’s chelation theory [84]. According to Overtone’s 
concept the lipid membrane surrounding the bacterial cell 
favors the passage of lipid soluble compounds and such lipid 
solubility is considered to be an important factor controlling 
antibacterial activity. Tweedy’s chelation theory explains 
how, upon complexation, involving membrane-permeable 
ligands such as phen, the polarity of the metal ion is reduced 
to a significant extent due to (i) overlap of the ligand orbitals 
and partial sharing of the positive charge of the metal ion 
with donor groups, (ii) delocalisation of π-electrons over the 
chelate ring as a whole, leading to an increase in the lipophil-
icity and lipid membrane penetration capability of the metal 
complex. This process can allow phen-based complexes to 
penetrate the cell membrane of bacterial cells and once em-
bedded in the cell membrane or inside the cell they can inter-
act with relevant biomolecules in the microorganisms, lead-
ing to inhibition of the cell growth and cell death [85, 86].  
Cell membrane permeability is a particular problem asso-
ciated with Gram-negative bacteria. Whereas there has been 
some modest success in the development of new drugs to 
treat Gram-positive bacteria, the situation obtaining for the 
development of drugs for Gram-negative species involves far 
less success [87, 88]. This situation is particularly concern-
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ing as there are very few drugs for Gram-negative bacteria in 
the development pipeline. In addressing this challenge it has 
recently been demonstrated that pre-exposure to silver Ag+1 
ions can potentiate the activity of a broad range of antibiotics 
against drug-resistant, Gram-negative bacteria by increasing 
their cell membrane permeability and thus restoring their 
antibiotic susceptibility [89].  
Sixty years ago Dwyer and his co-workers demonstrated 
the relationship between lipophilicity and antibacterial activ-
ity, for phen-complexes, when they demonstrated that the 
activity of [Ru(phen)3]2+ against a range of Gram-positive 
and Gram-negative bacteria was significantly improved 
through the introduction of methyl substituents on the phen 
ligands (Fig. 5), with the methylated complexes even dis-
playing moderate activity against Gram-negative bacteria 
[90]. The antimicrobial activity of ruthenium(II) polypyridyl 
complexes containing phen ligands has attracted significant 
attention more recently [91]. In a series of papers Keene and 
Grant, et al. have reported the antibacterial activities of a 
range of lipophilic mono-, bi-, tri- and tetra-nuclear Ru-phen 
complexes (Fig. 6) [92-97]. Based on their own experience 
and the evidence in the literature they concluded that the 
development of mononuclear polypyridylruthenium(II) com-
plexes as antimicrobials was limited due to their compara-
tively high MIC values when compared with that of state-of-
the-art antibiotics [91]. Although the mode of anti-bacterial 
action of these ruthenium(II) complexes is not fully under-
stood, DNA is considered to be their main target for biocidal 
activity.  
With the aim to develop better antimicrobials, Keene and 
Grant, et al. elected to design dinuclear and higher nuclear-
ity, enantiomeric, Rubbn, Rubbn-tri, Rubbn-tetra complexes, 
incorporating the lipophilic bbn ligands (bbn = bis[4(4′-
methyl-2,2′-bipyridyl)]-1, n-alkane; n = 2,5,7,10,12,14 or 16) 
(Fig. 6) [92]. Interestingly, the dinuclear complexes contain-
ing the short linking chains (bb2 and bb5) displayed very 
poor activity against the range of bacterial strains tested [92]. 
The more lipophilic Rubbn complexes (where n >5) exhib-
ited very good activity against Gram-positive and Gram-
negative strains (MIC = 1-16 µg/ml), and preliminary toxic-
ity studies indicated that the complexes were significantly 
less toxic to eukaryotic cells (IC50= >78 µg/ml). Further-
more, these Rubbn complexes were also very active against 
drug-resistant strains such as MRSA and VRE, with the 
Rubbn complexes with the more lipophilic longer linking 
aliphatic chains (Rubb12, Rubb14 and Rubb16) exhibiting the 
greatest activity (MIC = 1-4 µg/ml) [92]. Only slight differ-
ences in the anti-bacterial activity were observed between 
the enantiomeric forms of the complexes. The results of cel-
lular uptake studies correlated well with the activity profiles 
of these complexes, with the uptake following a similar trend 
(Rubb12 < Rubb14 < Rubb16; with LogP = -3.4, -2.7 and -1.9, 
respectively), a trend not observed for the mononuclear 
complexes, -[Ru(Phen)(bb7)]2+ and -[Ru(Me4Phen)3]2+ (Fig. 
6) [95]. Furthermore, the uptake in Gram-negative bacteria 
was significantly less when compared to that of the Gram-
positive species [95]. The dinuclear Rubbn complexes enter 
bacteria in an energy-dependent manner and they signifi-
cantly permeabilise the cell membranes [96], and interest-
ingly the most active compound, Rubb16, preferentially binds 
RNA and accumulates at the ribosomes in the bacteria [97]. 
These workers also showed that cellular uptake of the Rubbn 
complexes could be significantly increased by including la-
bile chloride groups on each metal centre but the resulting 
Cl- Rubbn complexes were found to be less active than their 
Rubbn counterparts [93]. Furthermore, the activity of the 
dinuclear complexes against eukaryotic cells varies depend-
ing on the lipophilic nature of the Rubbn ligand offering the 
possibility of making this class of complexes selective for 
bacteria [98]. 
These workers also examined the anti-bacterial activity 
of the tri- and tetra-nuclear complexes, Rubbn-tri and Rubbn-
tetra (Fig. 7) [94]. All of the tri- and tetra-nuclear complexes 
exhibited good antibacterial activity with the highly lipo-
philic linear complexes Rubb12-tri, Rubb16-tri, Rubb12-tetra 
and Rubb16-tetra displaying the most activity, up to four 
times more active than their dinuclear counterparts. Ironi-
cally, the trinuclear complexes were the most lipophilic but 
the tetra-nuclear complexes were generally more active. 
Generation of non-linear tetra-nuclear variants yielded com-
plexes that were slightly more lipophilic but they were con-
sistently less active when compared to their linear counter-
parts [93]. The level of cellular uptake of the Rubbn-tri and 
Rubbn-tetra complexes was similar in both Gram-positive 
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Fig. (5). (a) Structure of tris(phen)ruthenium(II) cation [Ru(phen)3]2+ and (b) structure of tris(3,4,7,8-tetramethyl-phen)ruthenium(II) cation, 
[Ru(3,4,7,8-Me4phen)3]2+. 
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Fig. (6). Structure of [Ru(phen)2(bbn)]2+, Rubbn, [Ru(3,4,7,8-Me4phen)3]2+, Rubbn-tri and Rubbn-tetra complexes.  
 
and Gram-negative species, the complexes were considera-
bly less active against the Gram-negative bacteria, an obser-
vation that the authors attributed to the fact that some Gram-
negative bacteria, particularly P. aeruginosa, may have in-
herent resistance to inert polypyridyl ruthenium complexes 
[91].  
In 2015, Keene and Collins et al. also reported the anti-P. 
aeruginosa (ATCC 27853) activities of the geometric iso-
meric complexes cis-α-[Ru(Phen)(bbn]2+ and cis-β-
[Ru(Phen)(bbn]2+ (n = 10 or 12) (Fig. 7) [99]. Whereas all of 
the [Ru(Phen)(bbn]2+ complexes displayed excellent activity 
against the Gram-positive S. aureus, only the cis-α-
[Ru(Phen)(bb12]2+ exhibited activity against Gram-negative 
species (E. coli and P. aeruginosa; MIC = 8 µg/ml for each 
species), with its activity being two to four times that of its 
isomeric form, cis-β-[Ru(Phen)(bb12]2+. Both cis-α-
[Ru(Phen)(bb12]2+ and cis-β-[Ru(Phen)(bb12]2+ readily accu-
mulate in the two bacteria, but significantly they displayed  
a much higher level of uptake in the P. aeruginosa.  
They also compared the activity and uptake profiles of  
the cis-α-[Ru(Phen)(bb12]2+ and cis-β-[Ru(Phen)(bb12]2+ with 
those of the previously studied mononuclear complexes 
[Ru(Me4Phen)3]2+ and [Ru(Phen)2(bb7]2+ (Fig. 6) and con-
cluded that the structural differences between the complexes 
are significant in terms of the interactions with the outer 
membrane of P. aeruginosa. They also postulated that it may 
be possible to modify this class of ruthenium complex to 
modulate their cell membrane interactive capabilities and 
essentially customize ruthenium complexes for activity 
against specific Gram-negative bacteria. 
In 2015, Wang et al. reported the anti-bacterial activity of 
the mononuclear ruthenium complex cation, 
[Ru(Phen)2(tip)]2+ (Fig. 8) [100]. [Ru(Phen)2(tip)]2+ exhib-
ited significant activity against Gram-positive (S. aureus) 
and Gram-negative (E. coli) bacteria (33% and 42% reduc-
tion in cell viability at 5µM concentrations, respectively). 
Cellular uptake studies on this complex indicated that there 
was 2-3 time more accumulation of [Ru(Phen)2(tip)]2+ in S. 
aureus than in E. coli. SEM and AFM observations on the 
morphology of the two bacteria indicated that contact with 
[Ru(Phen)2(tip)]2+ caused cell membrane disruption and cy-
toplasm leakage, and agarose gel electrophoresis studies in-
dicated that DNA and RNA damage were also key aspects of 
the anti-bacterial mechanism of action of [Ru(Phen)2(tip)]2+.  
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Fig. (7). Structures of [Ru(phen)(bbn)2]2+ complexes. 
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Fig. (8). Structure of [Ru(Phen)2(tip)]2+. 
 
In 1982, Smit et al. reported evidence that the enzyme 
inhibitory action of [Cu1(2,9-dimethyl-1,10-phenanthro- 
line)2]NO3, associated with its antibacterial capability, is a 
consequence of the toxicity of free copper ions and not that 
of the phenanthroline ligand [101]. They observed, using 
uptake studies with radiolabled 67Cu and [14C] 2,9-dimethyl-
1,10-phenanthroline, that significantly more copper than the 
2,9-dimethyl-1,10-phenanthroline accumulated in the cell 
wall of Mycoplasma gallisepticum cells. They concluded that 
the [Cu1(2,9-dimethyl-1,10-phenanthroline)2]+1 dissociated 
shortly after interaction with the cell membrane, that the 
copper ions were transported into the cytoplasm, and that the 
main function of the 2,9-dimethyl-1,10-phenanthroline ap-
peared to be as a transport vehicle for the copper. The posi-
tive charge of the Cu2+ ion renders it hydrophilic and in na-
ture uptake of copper ions relies on the presence of copper 
transporter proteins [102]. Such abnormal elevation of intra-
cellular copper, in the presence of membrane-permeable 
phen ligands, has become well established [101].  
More Li et al. have recently reported the antibacterial ac-
tivity of the series of mixed amino acid/phen copper(II) 
complexes, [Cu(phen)(L-Ser)(H2O)Cl], [Cu(phen) 
(Gly)(H2O)]Cl, [Cu(phen)(L-Ala)(H2O)]Cl, [Cu(phen)(L-
Phe)(H2O)]Cl and [Cu(phen)2Cl2] and CuCl2 against E. coli 
[103, 104]. These workers showed that the presence of the 
lipophilic phen ligand in the complexes (which presumably 
dissociate into [Cu(phen)(amino acid)]+ cations) can cause 
an elevation in the levels of intracellular copper when com-
pared to the CuCl2 salt. Furthermore, they found that the bis-
phen complex, [Cu(phen)2]2+, caused the greatest accumula-
tion of intracellular copper in the bacterium and when com-
pared to the antibacterial activities of the CuCl2 (IC50 = 120 
µg/ml) and the [Cu(phen)(amino acid)]+ complexes (IC50 
range = 24.3 - 31.4 µg/ml) it was found to be more active 
(IC50 = 7.5 µg/ml). They also showed that the acellular DNA 
binding and cleaving capabilities of this series of compounds 
and the copper salt followed the order [Cu(phen)2]2+ > 
[Cu(phen)(amino acid)]+ >> CuCl2. Interestingly, they also 
observed that all of the complexes could stimulate the 
growth of the E. coli at lower concentrations. The three 
[Cu(phen)(amino acid)]+ complexes, at a concentration of 16 
µg/ml, enhanced growth by 17.61- 40.85%, [Cu(phen)2]2+ at 
concentrations < 5 µg/ml stimulated growth by approxi-
mately 10%, and the copper salt CuCl2 had only a slight ef-
fect on growth of E. coli at low concentrations. The conclu-
sion was that the presence of phen in the complexes in-
creased their lipophilicity, improved the transport of copper 
into the cells, causing excessive intracellular accumulation of 
copper, and that the higher ratio of Cu: phen in [Cu(phen)2]2+ 
could explain its superior ability to induce the elevation of 
copper levels. Zou et al. also reported that phen ligands can 
cause abnormal elevation of intracellular copper [105].  
In 2012, Aldrich-Wright et al. reported the results of a 
preliminary anti-bacterial structure-activity study of a series 
copper(II) and paladium(II) cationic complexes with the 
general formulae, [Cu(IL)(AL)(H2O)]2+ and [Pd(IL)(AL)]2+ 
(where IL represents phen or 4-, 5-methylated or 4,7-, and 
5,6-dimethylated 1,10-phenanthrolines, and AL represents 
1,2-diaminoethane, 1S, 2S- or 1R,2R-diaminocyclohexane) 
[106]. The palladium(II) complexes displayed only minimal 
antibacterial activity, and whereas none of the complexes 
were active against P. aeruginosa the copper(II) complexes 
exhibited significant bactericidal activity against B. subtilis, 
S. aureus and E. coli (MIC ranges: 8-64 µg/ml; 8-32 µg/ml; 
8-32 µg/ml, respectively). 
These workers extended this study by examining the an-
tibacterial activities (S. aureus, E. coli and P. aeruginosa) of 
a series of complexes, [M(IL)(AL)]2+ (where M = Cu or Pt; 
where IL represents phen or 4-, 5-methyl, 4,7-, and 5,6-
dimethyl-, 3,4,7,8-tetramethyl-, 5-chloro-, 3,8-dibromo-, 5-
nitro- and 4,7-diphenyl- 1,10-phenanthrolines, and AL repre-
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sents 1,2-diaminoethane, 1S, 2S- or 1R,2R-
diaminocyclohexane) (Fig. 9) [75]. Phen and the majority of 
the methylated-phen free ligands exhibited antibacterial ac-
tivity with MIC values in excess of 20 µM. The exception 
was the 4,7-diphenyl-1,10-phenanthroline which had supe-
rior activity against S. aureus and E. coli (MIC’s = 5-10 and 
10-20 µM, respectively). With the exception of the com-
plexes containing the 5-nitro-phen ligands, the copper com-
plexes were most active against S. aureus, and where they 
contained the methyl-, chloro-, bromo-, and 4,7-phenyl- 
functionalized phen ligands they exhibited a significant in-
crease in activity when compared to their unsubstituted phen 
containing analogues. In this series the most active com-
plexes were the complexes containing the 3,4,7,8-
tetramethyl- and 4,7-diphenyl- substituted phen ligands 
(MIC’s = 1.25-2.5 µM). No significant differences were ob-
served between the RR- and SS- enantiomers of the copper 
complexes. The platinum(II) complexes were found to be 
selective for E. coli. (Growth Inhibition GI50 = 10-20 µM), 
with no discernible added value accruing from replacing the 
unsubstituted phen with the 4- and 5-methyl, 4,7-, and 5,6-
dimethyl- and , 5-chloro- functionalized phens. The com-
plexes containing the 3,4,7,8-tetramethyl-phen ligand had 
the lowest activity against E. coli (GI50 > 20 µM). Further-
more, the mono-, di- and tetra-methylated phen derivatives 
exhibited decreasing anti-E. coli activity in that order, which 
is in contrast to the activity observed for the free ligands 
themselves.  
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Fig. (9). The general structure of copper(II) and platinum(II) metal 
complexes where M = Cu or Pt. * Indicates a chiral centre, R3-8 
represent functionalised positions [75]. 
 
To probe the different activity profiles of the copper(II) 
and platinum(II) complexes further these workers examined 
the cell membrane permeabilisation capabilities (over a short 
period - 25 mins) of the four most active complexes, 
[Cu(4,7-diphenyl-phen)(AL)]2+ and [Pt(phen)(AL)]2+ (where 
AL = 1S, 2S- and 1R,2R-diaminocyclohexane). The results 
suggested that the two copper complexes exert a substantial 
degree of membrane permeabilisation to S. aureus cells, pos-
sibly due to interaction with teichoic acid as a target. In con-
trast the platinum complexes did not exhibit significant dis-
ruption to E. coli membrane integrity. Interestingly, in a later 
report these worker showed that the [Cu(IL)(AL)]2+ com-
plexes (where IL represents phen or 5-methyl, 5,6-dimethyl-, 
3,4,7,8-tetramethyl- and 4,7-diphenyl-phen) did not induce 
lyses in red blood cells, and called into question their cell 
membrane activity [107]. These workers attribute the lack of 
activity of the copper and platinum complexes against P. 
aeruginosa to reduced cellular uptake due to its lack of cell 
membrane permeability (8% of that of E. coli) and the possi-
ble role of efflux mechanisms, provided by transport proteins 
associated with the ‘intrinsic’ antibiotic resistance of this 
microbe.  
It is further postulated that compared to the stable plati-
num complexes that the copper complexes, [Cu(IL)(AL)]2+, 
are labile and that their speciation products in solution are 
likely responsible for the variation in their mode of action. It 
is also proposed that their antibacterial activity is not simply 
a sum of their components (metals and ligands), noting that 
the mono-phen complexes such as [Cu(5,6-dimethyl-
phen)(AL)]2+ are slightly more active against S. aureus (MIC 
= 2.5-5.0 µM) than bis-phen complex such as [Cu(5,6-
dimethyl-phen)2]2+, reported earlier by Dwyer et al. (MIC = 
4.0-7.9 µM) [43]. Furthermore, the metal-free phen and the 
majority of its functionalised derivatives were reported to 
primarily affect Gram-negative bacteria and upon coordina-
tion in the [Cu(IL)(AL)]2+ complexes results in a reduction in 
activity against the Gram-negative species and an increase in 
activity against S. aureus. These workers suggest that the 
stable platinum complexes may be entering the E. coli cells 
through an, as yet, unknown mechanism.  
DNA AS AN ANTIBACTERIAL TARGET FOR 
METAL-PHEN COMPLEXES 
DNA offers an interesting, underexplored, target for po-
tential antimicrobials, and this is an approach currently at-
tracting significant attention [108]. In 1979 Sigman et al. 
reported the oxidative DNA cleavage capability of 
[Cu(phen)2]2+ in the presence of a reductant [109]. Since this 
discovery many metal complexes containing phen ligands 
have been reported to interact and cleave DNA, with the 
phen ligands increasing the intercalative properties of the 
complexes.  
Several groups have reported the antibacterial activity of 
ternary metal(II)-phen complexes (metal = Cu2+, Ni2+, Co2+, 
Mn2+) containing known quinolone/fluoroquinolone antibiot-
ics [110-130]. The structural features and the broad biologi-
cal activity of such complexes containing Cu2+, Ni2+, Co2+ 
and Zn2+ have been described in a recent review [131]. The 
quinolone’s are synthetic antibacterial agents which target 
the DNA-replication enzyme gyrase (type II topoisomerases) 
and topisomerase IV [132]. Upon formation of binary com-
plexes with metals such as copper(II) the ability of qui-
nolones, such as iomefloxacin (Fig. 10), to bind DNA is sig-
nificantly increased, but the complexes are not stable at 
physiological pH [131]. The addition of phen to 
[Cu(quinolone)]2+ yields very stable ternary complexes (Fig. 
10), which are capable of binding DNA in an intercalative 
mode, are nuclease active, and possess a cellular uptake 
route different to that of the free quinolone drugs [128-130]. 
Furthermore, the use of a mutant strain of E. coli, devoid of 
porins, proteins responsible for the filtration of hydrophilic 
compounds in Gram-negative bacteria [76], have shown that 
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Fig. (10). The structure of lomefloxacin and its ternary copper(II) complex with phen [Cu(lomefloxacin)(NO3(phen)]. 
 
[Cu(quinolone)(phen)]2+-type complexes are hydrophobic 
and that they enter the cells in a porin-dependent manner 
[130]. Similar DNA binding and/or nuclease capabilities 
have been implicated in the antibacterial mechanism of ac-
tion of a range of similar mono-phen complexes containing 
non-quinolone donor ligands and metal centres such as Ag1+ 
[133], Cu1+[134, 135], , Cu2+[114, 116, 136-141], Co2+[136, 
137], Ni2+[142], Co3+[143], Mn3+[144], Pd2+ [116], Pt2+ [75], 
Fe3+[145] and Zn2+ [146]. Furthermore, several cationic bis-
phen complexes with the general formula [ML(phen)2]2+ ( M 
= Cu2+, Zn2+, Ni2+,Y3+ Pd2+ and Dy3+) have also been re-
ported to bind/cleave DNA and they exhibit clinically rele-
vant antibacterial activity against Gram positive and Gram 
negative bacteria [116, 147-152]. Cationic Cu(phen)2+ and 
Cu(phen)22+ moieties have also been incorporated into po-
lymeric conjugates, which are also capable of binding and 
cleaving DNA and which also exhibit clinically relevant an-
tibacterial activity against Gram positive and Gram negative 
bacteria [153, 154].  
The ruthenium(II) polypyridyl complexes are well known 
for their ability to interact with DNA [155]. Keene and Grant 
et al. have reported the antibacterial activities of a range of 
lipophilic mono-, bi-, tri- and tetra-nuclear Ru-phen com-
plexes (Fig. 6 and Fig. 7) [92-99], and they attribute their 
biological activities to their ability to interact and damage 
DNA. Indeed the dinuclear complex, [{Ru(Phen)2} (µ-
bb7)]2+ has been shown to bind chromosomal DNA from S. 
aureus [96]. Aldrich-Wright et al. explored the antibacterial 
activity of the mononuclear ruthenium complexes, [Ru(2,9-
dimethyl-phen)2(IL)]2+ (IL = a strong intercalating ligand such 
as dppz) (Fig. 11), which have proven DNA binding capa-
bilities [156]. These workers found that there was a direct 
correlation between the antimicrobial activity profile of the 
complexes and the affinity of the intercalating ligands for 
DNA, and they concluded that the observation was consis-
tent with a mode of action involving DNA-binding.  
Although many metal complexes containing phen ligands 
have been shown to bind DNA it should be noted that this 
property does not necessarily bestow antibacterial capability 
on them. Reedijk and Wezel et al. have recently reported the 
platinum chloride complexes, [Pt(phendione)Cl2] and 
[Pt(dppz)Cl2] (Fig. 12), which can intercalate DNA and ex-
hibit significant in vitro anticancer activity, but which are 
inactive against bacteria [60]. Starosta et al. reported the 
anti-S. aureus activity and plasmid DNA cleaving capabili-
ties of a series of cuprous iodide complexes incorporating 
phen or 2,9-dimethyl-phen with three different 
tris(aminomethyl)phosphane ligands (Fig. 13) [134]. They 
found that the complexes with the highest antibacterial activ-
ity exhibited the weakest ability to cleave the plasmid DNA. 
Chetna et al., tested the DNA nuclease and antibacterial ac-
tivities of the four binuclear copper(II) complexes, 
[Cu(oxpn)Cu(N-N)]2+ (where oxpn = N,N′-bis[3-
(methylamino)propyl] oxamide; N-N = bipy or phen or dpq 
or dppz) (Fig. 14) [140]. Although the DNA cleaving capa-
bility was in the order of [Cu(oxpn)Cu(dppz)]2+ > 
[Cu(oxpn)Cu(dqp)]2+ > [Cu(oxpn)Cu(phen)]2+ > 
[Cu(oxpn)Cu(bipy)]2+ only the bipy containing complex ex-
hibited appreciable antibacterial activity against the Gram-
negative E. coli. (MIC = 20 µg/ml). In our laboratory we 
have recently reported the in-vitro antibacterial activity of 
the water-soluble silver complex, [Ag2(phen)3(udda)] (ud-
daH2 = undecanedioic acid) (Fig. 15) [157]. 
[Ag2(phen)3(udda)] displays appreciable activity against E. 
coli (IC50 = 9.54 µM), S. aureus (IC50 = 14.18 µM), and P. 
aeruginosa (IC50 = 32.47 µM), and it is cytotoxic towards 
cisplatin-sensitive breast (MCF-7) and resistant ovarian 
(SKOV-3) cancer cell lines. It is an avid DNA binder with 
intercalative capability greater than that of the standard 
ethidium bromide, and yet it appeared to be incapable of 
inducing DNA damage in mammalian cells.  
Zhao et al. have reported the DNA binding and antibacte-
rial activities of the neutral ternary lanthanide complexes, 
[RE(sal)3(phen)] and [RE(cin)3(phen)] (RE = La3+, Pr3+, 
Nd3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Tm3+, Yb3+, Lu3+ ; 
salH = salicylic acid; cinH = cinnamic acid) [158, 159]. The 
complexes all bind to DNA in an intercalative mode and the 
strength of the binding is indirectly proportional to the size 
of the radius of the lanthanide cation in the complexes. Fur-
thermore, these workers found that the complexes displayed 
antibacterial activity against E. coli comparable to that of the 
free phen ligands, and that the activity followed the same 
trend as the binding capabilities of the complexes, with the 
complexes of the heavier metals more active than those con-
taining the smaller lanthanides. 
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Fig. (11). The structure of[Ru(phen)2(IL)]2+ (Where IL = dppz). 
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Fig. (12). Structures of (a)[Pt(phendione)Cl2] and (b) [Pt(dppz)Cl2]. 
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Fig. (14). Structure of the [Cu(oxpn)Cu(N-N)]2+ complexes (N-N = bipy or phen or dpq or dppz, respectively). 
 
Photocleavage of DNA 
A number of papers have been reported in the literature 
that describes antibacterial active phen–based complexes that 
cleave DNA when irradiated with light. In 2015, Sudhamani 
et al. reported that the copper complexes [Cu(mqt)(N-
N)H2O]1+ (mqt = 2-thiol-4-methylquinoline; N-N = phen, 
dpq or dppz) (Fig. 16) bind DNA in a groove binding mode 
and that they exhibit photonuclease capability with the 
photo-cleavage ability following the same order as the bind-
ing strengths of the three complexes, [Cu(mqt)(dppz)H2O]1+ 
> [Cu(mqt)(dpq)H2O]1+ > [Cu(mqt)(phen)H2O]1+ [160]. 
Mechanistic studies revealed the involvement of singlet oxy-
gen (1O2) in the photo-cleavage process, the three complexes 
exhibited potential in photodynamic antimicrobial chemo-
therapy (PACT) as they were also found to kill E. coli upon 
photo-irradiation by a tungsten-halogen 500W lamp. N. 
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Fig. (15). Structure of the water-soluble silver complex, [Ag2(phen)3(udda)] (uddaH2 = undecanedioic acid). 
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Fig. (16). Structure of [Cu(mqt)(N-N)H2O]1+. 
 
Raman et al. have reported the DNA binding and photonu-
clease capability of the bis-phen copper(II) complexes 
[Cu(dbdppo)(phen)2]2+ and [Cu(hnbdppo)(phen)2]2+ {dbdppo 
= (4-(3′,4′-dimethoxybenzaldehyde)2-3-dimethyl-1-phenyl-
3-pyrazolin-5-one; hnbdppo = (4- (3′-hydroxy-4′-
nitrobenzaldehyde)2-3-dimethyl-1-phenyl-3-pyrazolin-5-
one}[161]. The DNA cleavage reaction was found to be me-
diated by hydroxyl radicals generated by a photo-redox 
mechanism. The complexes were found to exhibit significant 
antibacterial activity but their PACT potential under photo-
irradiation was not investigated. Similarly, a number of other 
papers describe the photonuclease capability of bis-phen-
based complexes with Co3+ [162-165] and Ru2+ [165-168], 
along with their antibacterial capabilities, independent of any 
PACT-type studies. In 2014, Frei et al. reported the results 
of a study on the PACT potential of the known stable neutral 
bis-phen ruthenium complex, [Ru(DIP)2(bdt)] (DIP = 4,7-
diphenyl-phen; bdt = 1,2-benzenedithiolate) (Fig. 17) [169]. 
The phototoxicity of [Ru(DIP)2(bdt)] was found to be con-
siderably superior to the clinically approved photosensitizers 
porfimer sodium and 5-aminolevulinic acid, and the complex 
was efficient at killing Gram-positive bacteria. The DNA 
binding capabilities and the photochemical properties offered 
by metal complexes containing phen ligands presents sig-
nificant potential to contribute to the development of PACT. 
PACT is a relatively new avenue of research which offers an 
effective alternative approach in the era of antibiotic resis-
tance, whereby DNA is only one target, which can be ex-
ploited in tandem with a number of other targets to deliver a 
multimodal therapeutic approach for which bacterial resis-
tance has proved difficult [170]. 
INDUCTION OF OXIDATIVE STRESS 
It has recently been shown that some bactericidal antibi-
otics induce microbial cell death by stimulating the produc-
tion of destructive ROS, which can activate cellular respira-
tion, causing superoxide production and the liberation of iron 
ions from iron-sulphur proteins [171-174] which, in turn, 
catalyses hydroxyl radical formation via Fenton chemistry. 
These HO. radicals can induce microbial cell death by oxi-
dising proteins, lipids and DNA, [172-175] and can ulti-
mately trigger mutations which promote antibiotic resistance 
[176]. In defence, bacteria respond to ROS by deploying 
antioxidant enzymes (e.g. superoxide dismutase and cata-
lase) [175] and small antioxidant molecules like ascorbic 
acid and glutathione [177]. Additionally, microbially pro-
duced nitric oxide [178] and hydrogen sulphide [179] gas 
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molecules can each impede Fenton chemistry and promote 
antibiotic tolerance. There is also evidence to show that, un-
der conditions of nutrient deprivation, some bacteria can 
endure antibiotics due to the limited manufacture of pro-
oxidant metabolites and an increase in their antioxidant de-
fences [180]. 
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Fig. (17). Structure of [Ru(DIP)2(bdt)]. 
 
Metal-phen complexes such as [Cr(phen)3]3+ are known 
to generate ROS in bacteria, contributing to their antimicro-
bial activity [181]. The use of metal-phen-based photo sensi-
tizers in PACT also offers the potential to generate free radi-
cals in bacteria leading to oxidative lethal damage and/or 
apoptosis [169]. It has been shown that upon the addition of 
hydrogen peroxide, the antibacterial activity of metal-free 
phen is significantly enhanced against E. coli [182]. It was 
concluded that the Fenton reaction, which generates highly 
cytotoxic hydroxyl and perhydroxyl free radicals, could po-
tentially be catalysed through the in vivo formation of 
Fe3+/Fe2+-phen adducts. Furtado et al. later further examined 
this proposed pathway by repeating the exposure of E. coli to 
both phen and H2O2 in the presence of known Fe2+ and Fe3+ 
scavengers and, separately, in the presence of the free-radical 
scavenger, thiourea [183]. Interestingly, protection was 
achieved for the radical and Fe2+ scavengers (bipyridine, 
bipy), rather than the Fe3+ scavenger (desferal). It is notewor-
thy that these workers also found that neocuproine (2,9-
dimethyl-phen, Fig. 4), a known Cu1+ scavenger, also offered 
significant protection, supporting the notion that the known 
metallo-nuclease, [Cu(phen)2]1+, can play a role in bacterial 
cytotoxicity.  
INHIBITION OF ENZYMES 
According to the study of Zhu et al. in 2013, methyl-
transferase (MeTrCd) and acetyl-coenzyme A synthase 
(ACSCd) are two key enzymes in the acetylcoenzyme A 
synthesis pathway of the human pathogen Clostridium diffi-
cile, which is absent in humans and essential for the survival 
of the pathogen [184]. Screening inhibitors of the enzymes, 
the group has shown excellent inhibition effect of phen on 
ACSCd methyl group transfer and acetyl-coenzyme A syn-
thesis activity at 1 mM concentration. This inhibitory effect 
was further examined by checking the antibacterial activity 
of the inhibitor against C. difficile and, phen had an inhibi-
tory effect on the pathogen at 25 mM. This study suggests 
that 1,10-phenantrholine targets and inhibits these key en-
zymes interfering with the pathogen survival pathway. 
In 2009, Sharma et al. reported that the bacterial peptide 
deformylase (PDF) catalyses the removal of the N-terminal 
formyl group of proteins and it is essential for protein matu-
ration, growth and survival of bacteria [185]. Thus PDF be-
came a very attractive antimycobacterial drug target. In this 
study, various well-known PDF inhibitors, such as BB-3497, 
actinonin, 1,10-phenanthroline, hydroxylamine hydrochlo-
ride and galardin, were selected to evaluate their inhibitory 
activity against Mycobacterium tuberculosis. All compounds 
were active against M. tuberculosis, displaying a bacte-
riostatic mode of inhibition (MIC9 values ranging from 0.2-
74 mg/L), but BB-3497 and 1,10-phenanthroline exhibited 
the most potent in vitro antimycobacterial activity with 
MIC’s of 0.25 and 0.8 mg/L, respectively, suggesting the 
potential of these promising PDF inhibitors against M. tu-
berculosis. 
In a study by Upadhye et al., in 2009 the effects of ser-
ine, a metalloprotease inhibitor, have been evaluated on my-
cobacterial ES-31 serine protease, to assess the importance 
of this enzyme for bacterial cell growth [186]. 1,10-
phenanthroline was tested and at a concentration of 0.5 mM 
it inhibited 78% of mycobacterial ES-31 serine protease ac-
tivity in vitro. 1,10-phenanthroline also showed a decreased 
bacterial growth in 61% in axenic culture at 0.1mM and the 
inhibition was further confirmed by a decreased amount in 
73% of ES-31 serine protease secreted in the culture filtrate. 
In human macrophage culture, 1,10-phenanthroline inhibited 
the infectivity of virulent and avirulent M. tuberculosis ba-
cilli to macrophages by 68% and 63% growth inhibition of 
each respectively. It was observed that addition of mycobac-
terial ES-31 serine protease to macrophage culture enhanced 
the entry of bacilli and their multiplication in human macro-
phages, however, the addition of 1,10-phenanthroline 
strongly inhibited the mycobacterial growth as observed by 
decreased CFU count, showing the importance of mycobac-
terial ES-31 serine protease for pathogen infectivity. 
In their pioneering work Dwyer et al. identified the en-
zyme inhibitory activity of polypyridyl metal complexes 
when they found that they could deactivate acetylcho-
linesterases [90], opening up the possibility of developing 
phen-based complexes that target enzymes in bacteria. In 
2013, Tarushi and co-workers reported the antimicrobial 
activities of Zn(II) complexes with the general formula 
[Zn(quinolone)(phen)Cl] (quinolone = flumequine, oxolinic 
acid and enrofloxacin) [187]. The group reported that all 
complexes possessed a potent antibacterial activity against B. 
subtilis, B. cereus, S. aureus and E. coli, exhibiting very low 
MIC values in the range and 2–10 µg/mL. The complexes 
were also found to interact DNA in an intercalative binding 
mode, but their antibacterial activity was also attributed to 
their ability to inhibit DNA replication by targeting essential 
type II bacterial topoisomerases such as DNA gyrase and 
topoisomerase IV. 
Recently, the antibacterial activities and the alkaline 
phosphatase (ALP) inhibitory capability of the metal-free 
phen and the ternary copper(II) complexes, [Cu(phen) 
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(meimzH)(H2O)2]2+ and [Cu(phen)(cnge)(H2O)(NO3)2 
(meimzH = methylimidazol; cnge = cyanoguanidine) were 
examined [141, 188]. It was demonstrated that metal-free 
phen was an effective inhibitor of ALP and it was postulated 
that the mode of action was associated with the sequestration 
of Zn2+ ions from the active site of the enzyme. The two 
phen-based complexes, [Cu(phen)(cnge)(H2O)(NO3)2] and 
[Cu(phen)(meimzH)(H2O)2]2+ were also reported to exhibit 
an inhibitory effect with their mode of action attributed to a 
ligand-substitution mechanism involving the ALP protein.  
ACTIVITY OF METAL-PHEN COMPLEXES ON 
BIOFILMS 
1,10-phenanthroline-5,6-dione (phendione) (Fig. 4), has 
been shown to be active against Enterococcus, with the abil-
ity to eradicate E. faecalis biofilms, and its activity appears 
to be related to its ability to sequester Zn2+ ions from met-
allo-enzymes [28]. The authors did not know exactly how 
phendione eradicated the E. faecalis biofilm, but they specu-
lated that phendione may weaken the extracellular polymeric 
substances of the biofilm by disrupting the Zn2+ balance, and 
allowing the compound to get into bacterial cells harbored 
deep within the biofilm to exert its antimicrobial effects as a 
metalloprotease inhibitor. In 2014 Katzianer et al. reported 
the results of the antimicrobial activity of 5-nitro-phen 
against Clostridium difficile [189]. 5-nitro-phen showed po-
tent bactericidal effects in vitro and it was shown to inhibit 
the growth of all three tested C. difficile strains efficiently 
(MIC ≈2 µM) at concentrations comparable with the first-
line drug metronidazole. In the same study, 5-nitro-phen 
promoted C. difficile biofilm dispersal. For this assay, 
biofilm associated cells of C. difficile were incubated with 
the compound for different times and the remaining biofilm 
was quantified by crystal violet staining. The biofilm-
associated biomass was significantly reduced in tests involv-
ing 6 h and 24 h exposures, suggesting that 5-nitro-phen may 
promote C. difficile biofilm dissolution. Additionally, the 
group examined the efficacy of 5-nitro-phen in a murine 
model and the compound displayed modest in vivo effects 
against C. difficile infection. For this test, mice were infected 
with C. difficile and were treated with the compound (5 
mg/kg or 10 mg/kg doses). Although 100% of mice were 
moribund following 2 days of infection, treatment groups 
likewise survived significantly better, suggesting that 5-
nitro-phen has a modest effect on C. difficile infection in 
vivo. 
There are very few reports in the literature describing the 
anti-biofilm activity of phen-based complexes. In 2016, Vi-
ganor et al. also reported the antibacterial activity of phendi-
one against P. aeruginosa and its biofilm, [190]. The phen-
dione was found to be significantly more active against the 
pathogen than the parent phen (MIC90 = 12.50 µg/ml and 
200 µg/ml against susceptible and resistant isolates, respec-
tively) Furthermore, pretreatment of the bacteria with phen, 
phendione and the Cu2+ and Ag1+ complexes, 
[Cu(phendione)3]2+ and [Ag(phendione)3]+ (Fig. 18), at 0.5 x 
MIC values inhibited biofilm formation. [Cu(phendione)3]2+ 
and [Ag(phendione)3]+ were particularly active, reducing 
both biomass (by 48% and 44%, respectively) and viability 
(by 78% and 77%, respectively). Furthermore, phen, phendi-
one, [Cu(phendione)3]2+ and [Ag(phendione)3]+ also dis-
rupted mature biofilm, in a dose dependent manner, with the 
metal complexes being particularly active (IC50 = 9.39 µM 
and 10.16 µM, respectively). These results are particularly 
significant given the resistance issues associated with P. 
aeruginosa which is a pathogen typically isolated from 
nosocomial infections, which is emerging as a particular 
global healthcare problem as the emergence of MDR isolates 
of this species is limiting the number of effective antimicro-
bials that are available to treat infected patients [190-193].  
The anti-biofilm capabilities of the copper(II) complexes, 
[Cu(IL)(AL)]2+ (where IL represents phen, 5-methyl, 5,6-
dimethyl-, 3,4,7,8-tetramethyl-, and 4,7-diphenyl- 1,10-
phenanthrolines, and AL represents 1,2-diaminoethane, 1S, 
2S- or 1R,2R-diaminocyclohexane) (see Fig. 8 for the gen-
eral structure), against S. aureus have been demonstrated 
recently [107]. Although the MIC values for the copper 
complexes (MIC range = 2-32 µg/ml) are significantly 
higher than that of the antibiotic vancomycin (MIC = 0.25 
µg/ml), their anti-biofilm activities are significantly better. 
For vancomycin a minimum of 100 µg/ml (equivalent to 400 
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Fig. (18). Structure of (a) [Cu(phendione)3]2+ and (b) [Ag(phendione)3]+. 
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fold the MIC) was required to get an appreciable reduction 
(approximately 44%) in the biomass in the S. aureus biofilm, 
whereas for example 25 µg/ml of [Cu(5,6-dimethyl-
phen)(SS-dach)]2+ (equivalent to 3 fold the MIC) rapidly (2 
h) reduced the biofilm by 68%. All of the copper complexes 
had similar activity against the biofilm. Replacing the Cu2+ 
in [Cu(5,6-dimethyl-phen)(SS-dach)]2+ with Pt2+ and Pd2+ 
significantly reduces the antibacterial and anti-biofilm activi-
ties. It was suggested that the nuclease capability of the cop-
per complexes (which is not a feature of the platinum and 
palladium complexes) may be a significant factor in their 
mechanism of action against both planktonic and biofilm 
growing cells, particularly given that the extracellular matrix 
of biofilms are known to contain significant levels of nucleic 
acids. 
CONCLUDING REMARKS 
Bacterial resistance to antibiotics now represents one of 
the greatest challenges to public health, globally. In an effort 
to address the diminution of the therapeutic options in this 
“era of resistance” there is a pressing need to identify anti-
bacterial agents that can either target bacteria in ways that 
are different to the current arsenal of antibiotics or that can 
kill bacteria in a multimodal fashion, thereby preventing the 
rapid onset of resistance. In the 1950’s, 1960’s and 1970’s 
work, pioneered by Francis Dwyer, on the antibacterial ac-
tivity of metal complexes containing 1,10-phenanthroline 
ligands [90, 93], opened the door to the development of the 
diverse biological profile of this class of inorganic com-
pound [44]. These early results clearly demonstrated the an-
tibacterial chemotherapeutic potential of metal complexes of 
1,10-phenanthroline, but the significance of the results was 
not embraced by the pharmaceutical sector as the “antibiotic 
era” was at its height and antibiotic resistance was not appre-
ciated as an insurmountable problem.  
As we are now aware the “antibiotic era” has been char-
acterized by the overuse and misuse of antibiotics, culminat-
ing in the present critical “era of resistance”. Consequently, 
there has been a recent surge in interest in the antimicrobial 
applications of metal-based compounds, with the application 
of metal complexes incorporating 1,10-phenanthroline 
ligands playing a significant role. 1,10-phenanthroline exerts 
in vitro antimicrobial activity against a broad-spectrum of 
bacteria, in its own right. The antimicrobial activity of 1,10-
phenanthroline can be significantly modulated by modifying 
its structure. The development of metal-phen complexes af-
fords the medicinal chemist an opportunity to exploit such 
structural diversity by introducing a variety of metal centres, 
offering the opportunity to control characteristics such as the 
geometry, lipophilicity, redox status, ability to generate 
beneficial reactive oxygen/nitrogen species and the ability to 
interact with biomolecules such as DNA and proteins. Metal 
complexes of phen-type ligands are generally more active 
than the metal-free ligand and the efficacy of such com-
plexes can be further improved by introducing auxiliary 
ligands, such as the quinolones, which are themselves bioac-
tive. The study of metal-phen complexes as potential anti-
bacterials is in its infancy and although this review presents 
an encouraging perspective with respect to the potential for 
the deployment of such inorganic therapeutics in the fight 
against bacteria the transfer of the results of the in vitro stud-
ies into in vivo models remains largely unexplored. The tox-
icity profiles for phen and some metal-phen complexes in 
nematode [106], insect larval [32], and animal [58] models 
have been reported, with metal-free phen and some metal-
phen complexes displaying favorable tolerance levels. Since 
Dwyer early reports of in vivo activity [64, 90] very few in 
vivo bacterial infection studies have been carried out on phen 
and its metal complexes. The complex, [Ru(2,9-dimethyl-
phen)2(dppz)]2+ (Fig. 11), was recently shown to be active in 
rescuing the soil nematode Rhabditis elegans post infection 
with MRSA [156]. Data derived from appropriate in vivo 
models are necessary to ensure that effective drug delivery, 
low toxicity and optimal drug concentrations preventing bac-
terial cell proliferation can be achieved. DNA is assumed as 
a key target for metal-phen-based antibacterials and to date 
the vast majority of the data relating to this aspect of their 
activity has been based on acellular assays. There is a need 
to study the effects that the complexes are having on DNA in 
a cellular context using biochemical and established cell-
based spectroscopic techniques. Indeed, having researched 
this topic it is clear that there is dearth of knowledge in rela-
tion to how metal-phen complexes are interacting with a 
range of biomolecules within bacterial cells. Metal-phen 
complexes are clearly multimodal in their mechanism and 
there is a need to integrate what is currently known about the 
mechanisms into an advanced systems biology approach 
utilising novel ‘omics’ technologies with Bioinformatics. 
‘Omics’ technologies involve global and high-throughput 
analytical methods such as genomic microarrays, 2D-gel and 
2DLC/MS proteomics or biochemical reactions of metabo-
lites (metabolomics), ions (ionomics) or metals (metallom-
ics). These Omics technologies are supported by advanced 
Bioinformatic techniques and have been critical in providing 
information on key mechanistic targets and cellular path-
ways for many pharmaceutical agents. Integrated online da-
tabases with molecular networking of ‘omics’ data reveals 
relationships between novel complexes/drugs and functional 
molecules thus providing a widened biological perspective 
of the mechanisms of action. ‘Omics’ technologies are less-
time consuming and more efficient than traditional bio-
chemical techniques and are being widely adopted by many 
areas of biological and pharmaceutical research, however 
there are many recognised challenges which include data 
acquisition and analysis; modelling of multi-omics data sets 
for a systems biology approach and moreover the experimen-
tal preservation of an in situ state of metal-phen complexes 
in an already complex cellular system [194]. 
ABBREVIATIONS 
AFM = Atomic force microscopy 
ALP = Alkaline phosphatase 
AMR = Antimicrobial resistance 
BLM = Bleomycin 
DNA = Deoxyribonucleic acid 
EPS = Extracellular polysaccharides 
ESBL = Extended spectrum β-lactamases 
ESKAPE = Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter bau-
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manii, Pseudomonas aeruginosa and Entero-
bacteriaceae 
GBS = Group B Streptococcus 
GI = Growth inhibition 
HGT = Horizontal gene transfer 
HUVECs = Human umbilical vein endothelial cells 
MCF-7 = (Michigan Cancer Foundation) Human breast 
adenocarcinoma cell line 
MDR = Multidrug resitance 
MeTrCd = Methyltransferase 
ACSCd = Acetyl-coenzyme A synthase 
MIC = Minimum inhibitory concentration 
MRSA = Methicillin-resistant S. aureus 
OmpC = Outer membrane porin C 
OmpF = Outer membrane porin F 
PACT = Photodynamic antimicrobial chemotherapy 
PDF = Peptide deformylase 
PHEN = 1,10-phenanthroline 
RNA = Ribonucleic acid 
ROS = Reactive oxygen species 
SEM = Scanning electron microscopy 
SKOV-3 = (Sloan Kettering) Human ovary adenocarci-
noma cell line 
SN = Streptonigrin 
QS = Quorum sensing 
VRE = Vancomycin-resistant Enterococcus 
XDR = Extensively drug resistance 
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